Compositions and methods for treatment of thyroid eye disease
AssigneeViridian Therapeutics, Inc.
InventorsVahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
Life of this patent
Estimating the term…
Abstract
Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) with extended half-lives and uses thereof are provided herein. Antibodies and compositions described herein can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, by inhibiting the activity of IGF-1R with such antibodies and compositions.
Claims18
A method of treating thyroid eye disease (TED) in a subject having TED and in need thereof, the method comprising administering an anti-IGF-1R antibody comprising a light chain and a heavy chain, wherein
- a) the light chain comprises a light chain variable region comprising a LCDR1 having an amino acid sequence of SEQ ID NO:
- 53, a LCDR2 having an amino acid sequence of SEQ ID NO:
- 54, and a LCDR3 having an amino acid sequence of SEQ ID NO:
- 55, and
- b) the heavy chain comprises a heavy chain variable region and a Fc region, wherein the heavy chain variable region comprises a HCDR1 having an amino acid sequence of SEQ ID NO:
- 56, a HCDR2 having an amino acid sequence of SEQ ID NO:
- 57, and a HCDR3 having an amino acid sequence of SEQ ID NO:
- 58, and the Fc region comprising M252Y, S254T, and T256E substitutions wherein numbering is according to the Kabat numbering system.
A method of treating thyroid eye disease (TED) in a subject having TED and in need thereof, the method comprising administering to the subject an anti-IGF-1R antibody comprising a light chain and a heavy chain, wherein:
- a) the light chain comprises a LCDR1 having an amino acid sequence of SEQ ID NO:
- 53, a LCDR2 having an amino acid sequence of SEQ ID NO:
- 54, and a LCDR3 having an amino acid sequence of SEQ ID NO:
- 55;
- and
- b) the heavy chain comprises a heavy chain variable region and a Fc region,
- wherein the heavy chain variable region comprises a HCDR1 having an amino acid sequence of SEQ ID NO:
- 56, a HCDR2 having an amino acid sequence of SEQ ID NO:
- 57, and a HCDR3 having an amino acid sequence of SEQ ID NO:
- 58, and
- wherein the Fc region comprises an amino acid sequence of SEQ ID NO:
- 89.
Dependencies are inferred from the claim text.